Published in Blood on November 09, 2011
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell (2015) 2.13
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med (2014) 1.18
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica (2013) 1.06
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood (2014) 1.03
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97
Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica (2011) 0.93
Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol (2014) 0.85
BRAF Mutation in Hairy Cell Leukemia. Oncol Rev (2014) 0.81
Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. J Cancer Res Clin Oncol (2015) 0.78
MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32). Oncol Lett (2016) 0.77
Disease-specific mutations in mature lymphoid neoplasms: recent advances. Cancer Sci (2014) 0.76
Genomics of Hairy Cell Leukemia. J Clin Oncol (2017) 0.75
Discrepant results for BRAF V600E mutation among different specimens in a case of hairy cell leukemia. Ann Lab Med (2013) 0.75
Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. Int J Clin Exp Pathol (2014) 0.75
Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. Mod Pathol (2012) 0.75
Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. Sci Rep (2016) 0.75
Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion. PLoS One (2016) 0.75
Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. Haematologica (2016) 0.75
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. Front Pharmacol (2016) 0.75
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metab (2017) 0.75
Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. J Pathol Transl Med (2017) 0.75
Values of molecular markers in the differential diagnosis of thyroid abnormalities. J Cancer Res Clin Oncol (2016) 0.75
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med (2004) 3.26
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood (2006) 2.29
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica (2010) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood (2007) 2.10
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J (2005) 1.95
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol (2008) 1.90
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol (2013) 1.88
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood (2014) 1.87
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood (2013) 1.84
Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol (2008) 1.83
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood (2009) 1.80
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol (2006) 1.75
Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol (2006) 1.70
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol (2008) 1.68
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol (2007) 1.64
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood (2011) 1.63
Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med (2011) 1.61
Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood (2004) 1.59
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood (2011) 1.53
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One (2008) 1.52
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood (2011) 1.51
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood (2012) 1.48
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. Leuk Res (2011) 1.47
Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Leuk Lymphoma (2013) 1.47
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood (2005) 1.44
Primary bone lymphoma: experience with 52 patients. Haematologica (2003) 1.43
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. Leuk Lymphoma (2007) 1.43
Monoclonal gammopathy of undetermined significance: a new proposal of workup. Eur J Haematol (2013) 1.42
Congenital aggressive variant of Langerhans cells histiocytosis with CD56+/E-Cadherin- phenotype. Pediatr Blood Cancer (2009) 1.42
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol (2007) 1.42
[Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza")]. Med Clin (Barc) (2006) 1.42
CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case. Hum Pathol (2011) 1.40
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma. Leuk Lymphoma (2011) 1.40
Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood (2006) 1.38
Clinically based comments on the proposal for revision of the European Laryngological Society (ELS) classification of endoscopic cordectomies. Eur Arch Otorhinolaryngol (2008) 1.38
Ring sideroblasts and sideroblastic anemias. Haematologica (2011) 1.37
p53 lesions in leukemic transformation. N Engl J Med (2011) 1.34
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood (2013) 1.32
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood (2005) 1.31
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood (2013) 1.30
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood (2014) 1.30